Added to YB: 2025-08-19
Pitch date: 2025-08-16
ACOG [neutral]
Alpha Cognition Inc.
-32.15%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
Market Cap
$124.2M
Pitch Price
$8.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.15
P/E
-4.49
EV/Sales
11.95
Sector
Biotechnology
Category
N/A
Alpha Cognition 2Q25 Earnings Recap
ACOG (earnings update): Zunveyl AD drug launch sales $1.6M in Q2, below expectations due to misleading $1M April figure cited by COO that included stocking. PA requirements slowing fulfillment. Positive signs: 1 major insurer signed (17M lives), 65% of facilities reordering, OpEx guidance lowered to $34-38M. Cash $39M. Long-term outlook unchanged.
Read full article (3 min)